Protagonist Therapeutics, Inc (PTGX) Total liabilities 2017–2025
Protagonist Therapeutics, Inc (PTGX) total liabilities at each fiscal year-end, per SEC filings.
$53.5MFY2025 · since FY2017: $43.1M → $53.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $53.5M | -23.0% |
| FY2024 | $69.4M | +226.4% |
| FY2023 | $21.3M | -34.2% |
| FY2022 | $32.3M | -32.2% |
| FY2021 | $47.7M | +6.3% |
| FY2020 | $44.9M | -40.1% |
| FY2019 | $75.0M | +178.0% |
| FY2018 | $27.0M | -37.5% |
| FY2017 | $43.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More PTGX financial trends
PTGX RevenuePTGX Net incomePTGX Net marginPTGX Gross profitPTGX Gross marginPTGX Operating incomePTGX Operating marginPTGX Operating cash flowPTGX Free cash flowPTGX Capital expendituresPTGX Return on equityPTGX Stock buybacksPTGX Dividends paidPTGX Total assetsPTGX Shareholders’ equityPTGX overview →